While there is growing interest in the potential for intranasal oxytocin (IN-OT) to improve
social cognition and neurocognition (ie, nonsocial cognition) in schizophrenia, the extant …

Social cognition is impaired in people with schizophrenia and these deficits are strongly
correlated with social functioning. Oxytocin is a hypothalamic peptide that contributes to …

The administration of intranasal oxytocin (IN-OT) has demonstrated a wide range of effects
on social behavior and cognition, which has led to its proposed use as a treatment for …

The effects of intranasal oxytocin, a neuropeptide involved in prosocial behavior and
modulation of neural networks underlying social cognition and emotion regulation, have …

Background Negative symptoms are a core aspect of psychopathology in schizophrenia.
Currently available pharmacological agents have proven minimally efficacious for …

Schizophrenia is a heterogeneous disorder in which psychiatric symptoms are classified into
two general subgroups—positive and negative symptoms. Current antipsychotic drugs are …

Intranasal oxytocin (OT) has been suggested as a putative adjunctive treatment for patients
with schizophrenia and autism spectrum disorders (ASD). Here, we examine available …

Objective Findings on the efficacy of intranasal oxytocin (IN-OT) in schizophrenia have been
inconsistent. This meta-analysis of double-blind randomized controlled trials (RCTs) …

Background Individuals with schizophrenia have functionally significant deficits in automatic
and controlled social cognition, but no currently available pharmacologic treatments reduce …

Oxytocin has numerous prosocial and antipsychotic-like effects in animals. Prosocial effects
of acute intranasal oxytocin administration have also been reported in human subjects. We …